OMER stock forecast, quote, news & analysis
Omeros Corp is an inventive, commercial-stage biotechnology company that discovers and develops first-in-class protein and small-molecule therapeutics for large-market and orphan indications, with particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders... Show more
Why Omeros Corporation (OMER) Stock Is Down -10.5% in the Last 30 Days
Key Takeaways
- Omeros (OMER) shares have declined about 10.5% over the last 30 days, from a closing price of $18.49 to $16.55, following a second negative European regulatory opinion on its lead drug narsoplimab.
- The pullback trims, but does not erase, a powerful multi-month advance: the stock remains up roughly 74% over the trailing three months.
- The decline stems from a European regulatory setback rather than U.S. commercial fundamentals, where the launch of YARTEMLEA continues to accelerate.
- In late September, Cantor Fitzgerald upgraded the stock to Overweight with a $22 price target and a $400 million peak U.S. sales estimate, briefly sending shares to a 52-week high of $21.24.
Omeros Corporation (OMER) Company Overview and Market Position
Omeros Corporation (Nasdaq: OMER) is a Seattle-based commercial-stage biopharmaceutical company focused on complement-mediated diseases, cancers, and addictive and compulsive disorders. Its lead commercial product, YARTEMLEA (narsoplimab-wuug), is the first and only FDA-approved therapy for hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA) in patients aged two and older, and the first approved inhibitor of the lectin pathway of complement.
Beyond YARTEMLEA, the company's pipeline includes OMS1029 (a long-acting MASP-2 antibody), OMS527 (a PDE7 inhibitor in development for cocaine use disorder, funded by the National Institute on Drug Abuse), OMS805 (an AML-focused oncology candidate), and the T-CAT platform of recombinant antibodies targeting multidrug-resistant organisms. Omeros also sold global rights to the MASP-3 inhibitor zaltenibart to Novo Nordisk. Investors follow the stock for the commercial ramp of YARTEMLEA and the broader MASP-2 franchise.
Omeros Corporation (OMER) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, OMER has fallen about 10.5%, from a closing price of $18.49 to $16.55. The move was not a straight line: the stock spiked to a 52-week intraday high of $21.24 in late September before retreating sharply in mid-October after European regulators reaffirmed their rejection of narsoplimab.
The recent pullback contrasts with the broader multi-month trend. Over the trailing quarter, OMER has gained roughly 74%, climbing from about $9.53 in mid-July to its current level, even after the October decline. This reflects a sustained re-rating driven by the U.S. commercial launch of YARTEMLEA, which began in January 2026.
What Drove OMER Stock Price in the Last 30 Days
Two events framed the 30-day move. In late September, Cantor Fitzgerald upgraded Omeros to Overweight from Neutral with a $22 price target, citing a stronger-than-expected YARTEMLEA launch. The analyst raised the peak U.S. sales estimate to $400 million and projected 35% to 40% market share, sending shares to a 52-week high.
That momentum reversed on October 16, when the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) upheld its negative opinion on the marketing authorization application for narsoplimab in TA-TMA, reaffirming a decision first issued in June 2026. The shares dropped from $18.79 to a close of $16.20, a decline of about 13.8%. Omeros also said it would end its European compassionate-use program for YARTEMLEA due to rising U.S. demand, while working to enable reimbursed named-patient access in Europe where permitted.
What Drove OMER Stock Performance Over the Last Quarter
The quarterly advance has been powered by YARTEMLEA's U.S. commercial execution. For the second quarter of 2026, Omeros reported net revenue of $28.5 million, with YARTEMLEA gross sales of $32.2 million, up 190% sequentially. The company swung to net income of $13.2 million and ended June with about $132 million in cash and short-term investments, while generating positive operating cash flow.
Reimbursement milestones also supported the trend. A product-specific Medicare J-code took effect July 1, and a New Technology Add-On Payment (NTAP) for inpatient use became effective October 1, providing up to about $287,000 in additional Medicare reimbursement per case. Together with the Cantor upgrade, these developments lifted the stock from roughly $9 to $10 in mid-July toward its late-September peak.
Trending AI Robots
Tickeron's Trending AI Robots page highlights a curated selection of AI-driven trading bots drawn from a broader universe of hundreds of bots that trade thousands of tickers. Only the top-performing and most relevant bots are featured in this section, where each bot differs in strategy, timeframe, and performance metrics. Traders can review the selection to explore automated approaches across a range of market conditions. To see which AI robots are currently leading, visit the Trending AI Robots page.
OMER Stock Forecast Drivers: What Investors Should Watch Next
Near-term attention turns to Omeros' third-quarter results, which will show whether YARTEMLEA's U.S. uptake continued to accelerate and how the October NTAP reimbursement shift affects revenue. Investors are also watching the planned initiation of clinical studies in acute respiratory distress syndrome (ARDS) and in prevention of high-risk pediatric TA-TMA, targeted for later in 2026.
Additional factors include progress on OMS527 and OMS805, the path to named-patient access in Europe, and the company's capital position, given its roughly $132 million cash balance and reliance on a single commercial product. Regulatory, reimbursement, and competitive developments in the TA-TMA market could also influence the stock's trajectory.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
OMER's RSI Oscillator ascends from oversold territory
The RSI Oscillator for OMER moved out of oversold territory on October 19, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 28 similar instances when the indicator left oversold territory. In 25 of the 28 cases the stock moved higher. This puts the odds of a move higher at 89%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +2.16% 3-day Advance, the price is estimated to grow further. Considering data from situations where OMER advanced for three days, in 220 of 261 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
OMER may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 16, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on OMER as a result. In 67 of 88 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 76%.
The Moving Average Convergence Divergence Histogram (MACD) for OMER turned negative on September 28, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 42 similar instances when the indicator turned negative. In 39 of the 42 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
OMER moved below its 50-day moving average on October 16, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for OMER crossed bearishly below the 50-day moving average on October 20, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 9 of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 69%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where OMER declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
The Aroon Indicator for OMER entered a downward trend on October 21, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 9 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-22.922) is normal, around the industry mean (2.988). P/E Ratio (8.469) is within average values for comparable stocks, (-1.158). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (123.903) among similar stocks. P/S Ratio (35.714) is also within normal values, averaging (438.009).
The Tickeron SMR rating for this company is 11 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 36 (best 1 - 100 worst), indicating steady price growth. OMER’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 74 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 97 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. OMER’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of pharmaceutical products
Industry Biotechnology